Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · XBiotech Inc. (XBIT)

XBiotech CEO John Simard retires; Sushma Shivaswamy named interim CEO

Neutral Impact 4 of 5 leadership Written later

XBiotech's President and CEO John Simard is retiring effective December 8, 2025, and will remain Chairman of the Board. Chief Scientific Officer Sushma Shivaswamy has been named interim CEO while keeping her scientific role, with her base salary raised to $750,000; a permanent CEO has not yet been appointed.

Key points

  • John Simard retires as President and CEO effective December 8, 2025, and stays on as Chairman of the Board
  • Sushma Shivaswamy, 47, named interim CEO effective December 8, 2025, while continuing as Chief Scientific Officer
  • Shivaswamy's annual base salary increased to $750,000; bonus and full remuneration package to be set by the Compensation Committee later
  • Simard will serve in a consulting role; the company intends to pay the Severance Amount under his employment agreement

The filing

CompanyXBiotech Inc. (XBIT)
Form8-K, current report
Filed with the SECDec 9, 2025, 9:00 AM ET
Accession number0001171843-25-007836

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 09, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.